Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

"This is the computer of the age of AI": CEO Jensen Huang showcased two new "AI personal supercomputers," DGX Spark and DGX ...

OHSU's pioneering research, clinical trials led to better testing, approval for CTX disease Eric Stewart has a rare disease ...

Regenxbio reports promising microdystrophin expression data in DMD patients, with highest levels in 3-year-old. Plans FDA ...

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Signet Jewelers Limited ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Illumina Inc. and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250 ...

Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced the appointment of Phyllis Ferrell, MBA, DrPH, to its Scientific ...